James Gordon CFA
Stock Analyst at Barclays
(3.10)
# 2,550
Out of 4,574 analysts
136
Total ratings
58.8%
Success rate
4.8%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintained: Buy | $950 | $918.22 | +3.46% | 1 | Jul 24, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €900.00 → €950.00 | €815.30 | +16.52% | 14 | Jul 24, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 200.00 → CHF 210.00 | CHF 173.65 | +20.93% | 23 | Jul 24, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 120.00 → CHF 125.00 | CHF 126.90 | -1.50% | 9 | Jul 22, 2026 | |
| LON: GSK GSK plc | Maintained: Sell | 1,900p | 1,920p | -1.02% | 22 | Jul 21, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 530.00 | kr 457.40 | +15.87% | 1 | Jul 3, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 2,500 | kr 1,877 | +33.16% | 7 | Jul 2, 2026 | |
| SWX: SDZ Sandoz Group AG | Maintained: Buy | CHF 75.00 → CHF 81.00 | CHF 63.62 | +27.32% | 7 | Jul 1, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,500p | 12,670p | +30.23% | 13 | Jun 30, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Maintained: Sell | 1,350p | 1,582p | -14.66% | 3 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 410.00 | CHF 355.10 | +15.46% | 13 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | kr 300.00 | kr 320.60 | -6.43% | 16 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €85.00 | €76.03 | +11.80% | 6 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €22.00 | €24.50 | n/a | 1 | Jan 23, 2025 |
argenx SE
Jul 24, 2026
Maintained: Buy
Price Target: $950
Current: $918.22
Upside: +3.46%
argenx SE
Jul 24, 2026
Maintained: Buy
Price Target: €900.00 → €950.00
Current: €815.30
Upside: +16.52%
Galderma Group AG
Jul 24, 2026
Reiterated: Buy
Price Target: CHF 200.00 → CHF 210.00
Current: CHF 173.65
Upside: +20.93%
Novartis AG
Jul 22, 2026
Maintained: Hold
Price Target: CHF 120.00 → CHF 125.00
Current: CHF 126.90
Upside: -1.50%
GSK plc
Jul 21, 2026
Maintained: Sell
Price Target: 1,900p
Current: 1,920p
Upside: -1.02%
Swedish Orphan Biovitrum AB (publ)
Jul 3, 2026
Maintained: Buy
Price Target: kr 530.00
Current: kr 457.40
Upside: +15.87%
Genmab A/S
Jul 2, 2026
Maintained: Buy
Price Target: kr 2,500
Current: kr 1,877
Upside: +33.16%
Sandoz Group AG
Jul 1, 2026
Maintained: Buy
Price Target: CHF 75.00 → CHF 81.00
Current: CHF 63.62
Upside: +27.32%
AstraZeneca PLC
Jun 30, 2026
Maintained: Buy
Price Target: 16,500p
Current: 12,670p
Upside: +30.23%
Hikma Pharmaceuticals PLC
Jun 23, 2026
Maintained: Sell
Price Target: 1,350p
Current: 1,582p
Upside: -14.66%
May 26, 2026
Maintained: Buy
Price Target: CHF 410.00
Current: CHF 355.10
Upside: +15.46%
May 19, 2026
Maintained: Hold
Price Target: kr 300.00
Current: kr 320.60
Upside: -6.43%
Apr 23, 2026
Maintained: Hold
Price Target: €85.00
Current: €76.03
Upside: +11.80%
Jan 23, 2025
Downgraded: Sell
Price Target: €22.00
Current: €24.50
Upside: n/a